Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD + Ofatumumab in CD20+ ALL
NCT01363128Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2011
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and Burkitt lymphoma (BL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Complete Remission at 8 years, Overall Survival at 4 years and 1 more. Started Jul 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT01363128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01363128.